VIVES is a multi-sector fund that invests in projects with a positive societal impact
Sleep disorders affect over 2 billion people worldwide, with 1 billion suffering from obstructive sleep apnea, a condition linked to serious health issues such as hypertension, diabetes, and...
ViroVet is a pioneering company developing innovative technologies to combat viral diseases in livestock. They focus on antiviral drugs for complex respiratory illnesses and novel vaccines to protect...
Eligo Bioscience is the world leader in microbiome in vivo gene editing and is advancing a highly differentiated pipeline of precision medicines to address unmet medical needs in immunoinflammation...
Pierre Delatte, CTO and co-founder of Cissoid:
"With the VIVES fund, we have found a partner who understands the challenge of bringing technology from a university laboratory to the commercialization...
Eric de La Fortelle, Venture Partner at Seventure Partners:
"The tech transfer organization SOPARTEC and the associated fund VIVES played a key role in the initial structuring and the foundation of...
Georges Caron, past CEO Keemotion:
"VIVES supported us at the beginning of the project when the risk was at its maximum. We needed time to test some hypotheses and confront academic research with the...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is